Children's Hospital Colorado
Amanda Winters, MD, PhD
Cancer and Blood Disorders

Amanda Winters, MD, PhD

Instructor, Pediatric Hematology/Oncology/BMT

Specialties:
Hematology/Oncology - Pediatric , Pediatrics
Conditions:
Aplastic Anemia, Pediatric Cancer, Lymphoma, Leukemia (Childhood), Chemotherapy
See more
specialties:

Hematology/Oncology - Pediatric , Pediatrics

conditions:

Aplastic Anemia, Pediatric Cancer, Lymphoma, Leukemia (Childhood), Chemotherapy, Myelodysplastic Syndrome

Meet Amanda Winters, MD, PhD

I believe in providing the most evidence-based and compassionate care possible to my patients and their families. A diagnosis of cancer is one of the worst experiences of a family's life, and making it easier or more manageable to the child and his/her family in some small way is as important to me as providing physical healing. I and my colleagues also strive to treat patients with the most up-to-date in cancer therapies available.

Get to know her background

My clinical focus is in the treatment of children with cancer, in particular leukemias and conditions that may lead to leukemias such as inherited bone marrow failure syndromes or myelodysplastic syndromes (MDS).

Undergraduate 2004

University of Southern Mississippi (MS)

Medical School 2011

Tulane University School of Medicine

Graduate 2011

Tulane University School of Medicine

Internship 2012

Cincinnati Children's Hospital Medical Center Program

Residency 2014

Cincinnati Children's Hospital Medical Center Program, Pediatrics

Fellowship 2017

University of Colorado (Children's Hospital Colorado) Program, Pediatric Hematology / Oncology

For Patients:
I perform in-laboratory testing of new drugs that have been developed for acute myeloid leukemia (AML). These drugs are being tested in clinical trials in adults, and may be useful for children with AML as well. I'm also trying to develop more sensitive methods to detect molecular disease when it is not otherwise detectable after therapy, so we can more accurately know how much therapy is needed for individual patients.
For Referring Providers:
I am investigating targeted therapies for pediatric AML in the pre-clinical setting, including immunotherapies. In addition, I am developing droplet digital PCR assays as an alternative means to measure minimal residual disease in patients with AML.

Instructor, Pediatric Hematology/Oncology/BMT

PRODWEBSERVER1